Inflexion has announced the sale of its stake in pet supplements company Lintbells to Vetnique Labs, which is backed by Gryphon Investors. This transaction has resulted in a 5.5x return for Inflexion, marking a significant financial achievement.

Lintbells, known for its high-quality pet supplements, has been a part of Inflexion's portfolio, contributing to its growth and market presence. The acquisition by Vetnique Labs is expected to further enhance Lintbells' product offerings and market reach.

This sale underscores Inflexion's successful investment strategy and its ability to generate substantial returns for its stakeholders. The deal also highlights the growing interest and investment in the pet care industry, which continues to expand rapidly.

For more details on this transaction and other private equity news, visit Real Deals.